Fapon Unveils Innovative IVD Solutions at WHX Labs Dubai 2026

Dubai, UAE – Fapon, a frontrunner in the life sciences sector, is set to showcase its extensive range of in vitro diagnostic (IVD) solutions at the upcoming WHX Labs Dubai 2026, scheduled from February 10 to 13 at the Dubai World Trade Centre. Drawing from its two decades of industry expertise and advanced technologies, Fapon aims to spotlight pivotal offerings like its Alzheimer’s Disease (AD) blood testing solution. Through adaptable collaboration frameworks, the company supports local partners with comprehensive localization assistance, empowering them to enhance their IVD industries on a global scale.

Local Manufacturing Solutions for Enhanced IVD Capabilities

At the exhibition, Fapon plans to introduce its local manufacturing solutions, ranging from chemiluminescence immunoassay (CLIA) to molecular diagnostics. These solutions entail a thorough technology transfer process that encompasses core raw materials, reagent solutions, and open-system instruments. By providing research and development (R&D) expertise, alongside complete production processes, Fapon aids partners in establishing full local industrial capabilities. This enables them to effectively meet the demands of their regional markets, covering all aspects from R&D to commercialization.

Highlighting Advanced Alzheimer’s Disease Blood Testing

One of the key highlights at the expo is Fapon’s cutting-edge Alzheimer’s Disease (AD) blood testing solution, which includes an array of raw materials and bulk reagents for significant biomarkers like p-tau 217, p-tau 181, Aβ40, Aβ42, GFAP, and NfL. These biomarkers demonstrate both high sensitivity and specificity, aligning closely with established clinical diagnostic tests. This empowers IVD manufacturers around the world to create more accurate and reliable assays for Alzheimer’s diagnosis, marking a significant advancement in the field.

Comprehensive Chemiluminescence Solutions

Fapon will also demonstrate its extensive chemiluminescence solution portfolio, notably featuring the Shine series CLIA analyzers, which offer throughput capabilities ranging from 120 to 900 tests per hour. These high-performance analyzers are complemented by over 70 self-developed reagent solutions and essential raw materials. Additionally, Fapon showcases its robust selection of high-quality raw materials, including recombinant quality control and calibrator materials, thereby reinforcing its commitment to providing exceptional upstream support in diagnostic development.

Global Impact and Commitment to Healthcare Advancement

With a strong foundation of over 100,000 square meters of high-standard facilities and a worldwide R&D and manufacturing network, Fapon remains dedicated to bringing innovative, locally relevant solutions to the healthcare market. Currently, the company serves more than 70 countries and collaborates with over 2,500 organizations globally, reflecting its commitment to fostering stronger collaborations aimed at advancing regional healthcare initiatives.

Fapon continues to redefine the landscape of diagnostics and therapeutics through its state-of-the-art, AI-driven models. By merging innovative discoveries with one-stop diagnostic solutions and novel therapies, the company addresses the full spectrum of health management. Their services significantly accelerate the development of precision medicine, marking Fapon as a critical player in the ever-evolving healthcare landscape.

For updates and insights, follow Fapon on LinkedIn or visit their official site for more information.